Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1524 Articles

Chris Lange | Dec 13, 2017 at 11:05 AM EST

Why Cellectis Is Winning Big With Its Pfizer Partnership

Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two…

Chris Lange | Dec 12, 2017 at 10:40 AM EST

Short Sellers Can’t Make Up Their Minds on Major Pharma

The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Paul Ausick | Dec 11, 2017 at 4:01 PM EST

Disney, Apple Pace Dow to Monday Gain

Apple, Disney, Merck, and Pfizer were the leading gainers among the Dow 30 stocks on Monday. Bitcoin settled up 23%…

Jon C. Ogg | Dec 11, 2017 at 1:15 PM EST

Will Consumers Trust Generic Viagra?

A generic version of Viagra is coming to America, but will existing customers be willing to switch over to a…

Jon C. Ogg | Dec 6, 2017 at 10:05 AM EST

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately,…

Paul Ausick | Dec 5, 2017 at 4:01 PM EST

Disney, Intel Sink DJIA on Tuesday

Disney, Intel, Pfizer, and Verizon led Tuesday's drop in the DJIA.

Lee Jackson | Nov 30, 2017 at 10:00 AM EST

Merrill Lynch Bullish on Deep Value Pharmaceuticals: 5 Stocks to Buy for 2018

One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be…

Chris Lange | Nov 10, 2017 at 11:25 AM EST

Short Sellers Back Way Off Major Pharma

The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Lee Jackson | Nov 10, 2017 at 10:15 AM EST

Biosimilars Have Massive Sales Potential: 5 Top Drug Stocks to Buy Now

Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar…

Chris Lange | Oct 31, 2017 at 10:15 AM EDT

Pfizer Earnings Not Enough for Investors

When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to…

Chris Lange | Oct 30, 2017 at 11:15 AM EDT

What to Expect When Pfizer Reports Earnings

Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.

Chris Lange | Oct 29, 2017 at 10:25 AM EDT

Facebook, Alibaba and More Major Earnings to Look For This Week

The busiest earnings week of the season has come and gone, but there are still plenty more big names stepping…

Chris Lange | Oct 28, 2017 at 10:05 AM EDT

Top Biopharma Events Coming by the End of 2017

24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November…

Chris Lange | Oct 25, 2017 at 10:20 AM EDT

Short Sellers Hike Bets in Major Pharma

The October 13 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Oct 25, 2017 at 6:10 AM EDT

The 6 Most Shorted NYSE Stocks

Among the most shorted stocks traded on the New York Stock Exchange, two struggling retailers saw notable growth in their…

1 … 40 41 42 43 44 … 102

Pfizer : PFE

All Pfizer Articles

Why Cellectis Is Winning Big With Its Pfizer Partnership

Short Sellers Can’t Make Up Their Minds on Major Pharma

Disney, Apple Pace Dow to Monday Gain

Will Consumers Trust Generic Viagra?

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Disney, Intel Sink DJIA on Tuesday

Merrill Lynch Bullish on Deep Value Pharmaceuticals: 5 Stocks to Buy for 2018

Short Sellers Back Way Off Major Pharma

Biosimilars Have Massive Sales Potential: 5 Top Drug Stocks to Buy Now

Pfizer Earnings Not Enough for Investors

What to Expect When Pfizer Reports Earnings

Facebook, Alibaba and More Major Earnings to Look For This Week

Top Biopharma Events Coming by the End of 2017

Short Sellers Hike Bets in Major Pharma

The 6 Most Shorted NYSE Stocks

What JEPQ Actually Paid the Last Time the Nasdaq Fell 10%: a Stress Test for Its 10% Yield

VOO Is About to Become the First $1 Trillion ETF, and SPY Holders Are Paying 3x More for the Same Index

Laid Off at 58 With a 401(k) Loan, She Thought She Had 60 Days to Replace the Money. The Tax Code May Give Her Much Longer.

Laid Off at 58 With a 401(k) Loan, She Thought She Had 60 Days to Replace the Money. The Tax Code May Give Her Much Longer.

IRMAA Surprise: How Your 401(k) Distribution Today Triggers Medicare Surcharges Two Years Later

What JEPQ Actually Paid the Last Time the Nasdaq Fell 10%: a Stress Test for Its 10% Yield

VOO Is About to Become the First $1 Trillion ETF, and SPY Holders Are Paying 3x More for the Same Index

Pfizer : PFE

All Pfizer Articles

Why Cellectis Is Winning Big With Its Pfizer Partnership

Short Sellers Can’t Make Up Their Minds on Major Pharma

Disney, Apple Pace Dow to Monday Gain

Will Consumers Trust Generic Viagra?

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Disney, Intel Sink DJIA on Tuesday

Merrill Lynch Bullish on Deep Value Pharmaceuticals: 5 Stocks to Buy for 2018

Short Sellers Back Way Off Major Pharma

Biosimilars Have Massive Sales Potential: 5 Top Drug Stocks to Buy Now

Pfizer Earnings Not Enough for Investors

What to Expect When Pfizer Reports Earnings

Facebook, Alibaba and More Major Earnings to Look For This Week

Top Biopharma Events Coming by the End of 2017

Short Sellers Hike Bets in Major Pharma

The 6 Most Shorted NYSE Stocks

What JEPQ Actually Paid the Last Time the Nasdaq Fell 10%: a Stress Test for Its 10% Yield

VOO Is About to Become the First $1 Trillion ETF, and SPY Holders Are Paying 3x More for the Same Index

Laid Off at 58 With a 401(k) Loan, She Thought She Had 60 Days to Replace the Money. The Tax Code May Give Her Much Longer.

Featured Reads

Laid Off at 58 With a 401(k) Loan, She Thought She Had 60 Days to Replace the Money. The Tax Code May Give Her Much Longer.

IRMAA Surprise: How Your 401(k) Distribution Today Triggers Medicare Surcharges Two Years Later